Hepatocellular Carcinoma of Fibrolamellar Type in an Adolescent: Case Report and Literature Review
Overview
Authors
Affiliations
We present a female patient, 13 years old, with diagnosis of hepatocellular carcinoma of fibrolamellar type, which was rapidly evolving. The fibrolamellar hepatocellular carcinoma invaded more than 80% of the hepatic parenchyma without surgical possibility or liver transplantation. Measures applied corresponded to chemotherapy of 1 cycle of cisplatin 40 mg/s/5 days + vincristine 1.5 mg/m/day, 5-fluorouracil, doxorubicin, and dexrazoxane. The case presented aggressive evolution of hepatocellular carcinoma, which led to acute liver failure, with hyperammonemia, sepsis, pulmonary focus plus septic shock, grade III-IV encephalopathy, portal hypertension, and ascites with intra-abdominal hypertension. Death occurred due to multiple organ failure, which involved respiratory failure type KDIGO 1 and 2, acute liver failure, severe pneumonia, pericardial effusion, AKIN 2 acute kidney injury, carcinoma, and pulmonary metastasis. This type of ailment is infrequent in children and adolescents, and the first symptoms are crucial to achieve treatment possibilities.
Models of fibrolamellar carcinomas, tools for evaluation of a new era of treatments.
Song J, Lu M, He Z, Zhang W Front Immunol. 2024; 15:1459942.
PMID: 39582856 PMC: 11582006. DOI: 10.3389/fimmu.2024.1459942.
A framework for fibrolamellar carcinoma research and clinical trials.
Dinh T, Utria A, Barry K, Ma R, Abou-Alfa G, Gordan J Nat Rev Gastroenterol Hepatol. 2022; 19(5):328-342.
PMID: 35190728 PMC: 9516439. DOI: 10.1038/s41575-022-00580-3.